Gout Therapies Market Across 7MM To Reach USD 10.8 Billion in 2032

The sales of gout therapies in the seven major markets (7MM: the US, 5EU, and Japan) are expected to grow at a compound annual growth rate (CAGR) of 8.8 percent from $4.6 billion in 2022 to $10.8 billion in 2032, in line with rising disease prevalence and the introduction of novel agents, according to GlobalData.

According to "Gout Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs, and Forecast to 2032," there are nine late-stage medicines in the pipeline, the majority of which are urate-lowering therapies (ULTs) that will enter the US and Japanese markets beginning in 2025.

These ULTs are expected to total to $673 million in sales by 2032, equating to 6 per cent of the sales across the 7MM and the urate-lowering therapies class is expected to have the largest sales at $5.2 billion by 2032 with a CAGR of 13.1 per cent. These therapies are likely to adopted for patients with chronic gout or with hyperuricemia that is likely to lead to gout in the long-term, as per EP News.

Two more anti-inflammatory therapies are predicted to enter the market near the end of the projected period. Canakinumb, which is planned to arrive in 2030, is a biosimilar to the well-known Ilaris treatment. With Ilaris' US patent expiring in 2024, this biosimilar is expected to join the market, potentially reducing Ilaris' share.

In 2022, the gout market included multiple medication classes: anti-inflammatory treatments (AI) for acute attack treatment, Artificial intelligence for prophylaxis, and ULTs. Approximately 15 marketed medicines, several of which are now generics, produced a total of $4.6 billion in sales this year.